Quick Facts
| Peptide name | Popular Peptide Research Dosing Protocols |
|---|---|
| Research category | Evidence & Protocols |
| Primary research interest | Published study regimens, species, routes, durations, indications, and evidence limitations across the complete database |
Scope, coverage, and source-control method
This article covers every one of the 59 entries currently exported by the Peptide Basics database. “Peptide” is used as the database's broad research-library label: the list also contains approved drugs, non-peptide small molecules, SARMs, coenzyme mixtures, and polypeptide preparations. That distinction matters when interpreting evidence and regulatory status.
The database's consumer-facing dosage fields are not reproduced as evidence. Each historical regimen in the tables was accepted only when a primary publication, ClinicalTrials.gov record, or FDA label supplied enough detail to identify the species or study population, route, amount, duration, and research indication. The remaining entries say “no published regimen reported here.” That is an evidence finding—not proof that no paper exists anywhere—and it is preferable to filling a gap with an estimated schedule.
Historical study facts, not dosing instructions
Amounts and schedules below describe what a named study or label reported. They are not prescriptions, recommendations, stacking or cycling instructions, or instructions for handling a research product. Do not infer a human amount from an animal experiment or combine entries because they share an intended-research category.
| Coverage check | Count | Interpretation |
|---|---|---|
| Current database entries | 59 | Every entry is rendered exactly once in the research-group tables |
| Entries with a cited regimen | 21 | A primary paper, registry, or label reports enough protocol detail |
| Entries without a verifiable regimen | 38 | Explicitly marked; no estimated human or animal protocol is supplied |
How to read a research regimen
- Start with the species or population. A mouse, rat, macaque, healthy volunteer, and patient cohort answer different questions.
- Separate pharmacokinetic or pharmacodynamic challenges from treatment studies. A single intravenous secretagogue challenge is not a chronic body-composition protocol.
- Read the route and formulation exactly as reported. DAC and no-DAC CJC-1295, native GLP-2 and glepaglutide, and TB-500 and full-length thymosin beta-4 are not interchangeable.
- Treat duration as part of the regimen. A 28-day trial, a 72-week obesity trial, and a single-dose IVF trigger cannot be collapsed into a generic cycle.
- Use the limitation column as part of the result. A statistically positive endpoint in one population does not establish safety, efficacy, or regulatory status in another.
Several entries are not peptides at all. Tesofensine, MK-677, MK-2866, RAD-140, SLU-PP-332, CMS-121, 5-Amino-1MQ, and BAM-15 are small molecules or SARMs; NAD+ is a coenzyme, whereas glutathione is an endogenous tripeptide. Cerebrolysin and Cortexin are mixtures. Their inclusion reflects the current database, not a claim that they share peptide pharmacology.
Weight and metabolic research
This group includes approved incretin drugs, investigational agonists, small molecules, and preclinical metabolic compounds. The table preserves the species, route, duration, and indication of the cited work; it does not turn a trial arm into a recommendation.
| Database entry | Species or population | Route and historical study regimen | Duration | Indication or research question | Evidence limitation | Primary source |
|---|---|---|---|---|---|---|
| Semaglutide | Adults with overweight or obesity without diabetes (n=1,961) | Subcutaneous once weekly, escalated to a 2.4 mg target dose | 68 weeks, including the study escalation period | Weight management with lifestyle intervention | A controlled trial in a defined population; the result does not validate unapproved formulations or individualized schedules. | STEP 1, PubMed 33567185 |
| Tirzepatide | Adults with obesity without diabetes (n=2,539) | Subcutaneous 5, 10, or 15 mg once weekly, with a 20-week escalation period | 72 weeks | Weight management with lifestyle intervention | Phase 3 results are population- and titration-specific; tirzepatide is a dual agonist, not a proxy for other entries. | SURMOUNT-1, PubMed 35658024 |
| Retatrutide | Adults with obesity (phase 2 trial) | Subcutaneous once weekly: 1, 4, 8, or 12 mg arms; higher arms began at 2 or 4 mg and escalated every 4 weeks | 48 weeks | Weight management research | Investigational triple agonist; phase 2 findings do not establish an approved regimen or long-term safety. | Retatrutide phase 2, PubMed 37366315 |
| AOD 9604 | Obese Zucker rats | Oral AOD-9604 500 micrograms/kg once daily | 19 days | Body-weight gain and adipose-tissue lipolysis research | Rat study; this amount is not a human dose, and later human development does not validate an online schedule. | AOD-9604 metabolic study, PubMed 11146367 |
| Tesamorelin | Adults with HIV-associated lipodystrophy and excess abdominal fat | Subcutaneous 2 mg once daily in the pivotal study program | 26 weeks in the cited trial; longer follow-up was separately studied | Reduction of visceral adipose tissue in HIV-associated lipodystrophy | The study population and formulation matter. The current EGRIFTA SV label uses a 1.4 mg daily dose from a 2 mg/vial formulation, whereas the cited pivotal trial used 2 mg daily; neither is a protocol for research products. | Falutz et al., PubMed 18057338 and FDA EGRIFTA SV label |
| Tesofensine | Adults with obesity, BMI 30 to 40 kg/m² (n=203) | Oral 0.25, 0.5, or 1.0 mg once daily after a 2-week run-in | 24 weeks | Weight-loss research with an energy-restricted diet | Tesofensine is a small molecule, not a peptide; cardiovascular and central-nervous-system effects limit generalization. | Astrup et al., PubMed 18950853 |
| SLU-PP-332 | No verifiable human protocol identified | No human regimen reported here | Not established | ERR-alpha metabolic and exercise-mimetic research | An early small-molecule research compound; the database entry must not be read as a human protocol. | No verified human protocol located in the reviewed primary sources |
| 5-Amino-1MQ | No verifiable human protocol identified | No human regimen reported here | Not established | NNMT-inhibition and metabolic research | Preclinical NNMT-inhibition findings do not establish a human amount, route, duration, or safety profile. | No verified human protocol located in the reviewed primary sources |
| Cagrilintide | Adults with overweight or obesity | Subcutaneous self-injection once weekly at 0.3, 0.6, 1.2, 2.4, or 4.5 mg | 26-week treatment period, with up to 6 weeks of escalation, followed by 6 weeks of follow-up | Weight management research | Dose-finding phase 2 study; investigational amylin analogue, and the trial schedule is not a general recommendation. | Lau et al., PubMed 34798060 |
| Adipotide | Spontaneously obese rhesus macaques; separate GLP safety cohorts | Subcutaneous 0.43 mg/kg once daily in the fixed-dose efficacy study; 0.25, 0.43, and 0.75 mg/kg were used in safety cohorts | 28 consecutive days, followed by a 28-day recovery period | White-fat targeting, weight, and insulin-resistance research | Nonhuman-primate study with dose-dependent, reversible renal findings; no human protocol or conversion is established. | Barnhart et al., PubMed 22072637 |
| BAM 15 | No verifiable human protocol identified | No human regimen reported here | Not established | Mitochondrial uncoupling and energy-expenditure research | Preclinical uncoupler data carry substantial translation and toxicology uncertainty; no human schedule was accepted. | No verified human protocol located in the reviewed primary sources |
Growth-hormone, muscle, and body-composition research
Growth-hormone secretagogues, SARMs, IGF analogues, and myostatin-related compounds are often grouped together in online schedules even though their chemistry, receptors, and evidence differ substantially.
| Database entry | Species or population | Route and historical study regimen | Duration | Indication or research question | Evidence limitation | Primary source |
|---|---|---|---|---|---|---|
| CJC-1295 (No DAC) | Healthy adults aged 21–61 years | Subcutaneous CJC-1295 with DAC; ascending single- and repeat-dose studies included reported doses of 30 or 60 micrograms/kg | 28- and 49-day study designs; repeat administrations were weekly or biweekly | Growth-hormone and IGF-1 pharmacology | The published work concerns the DAC form; it cannot be transferred to no-DAC/Mod GRF products or combined schedules. | Teichman et al., PubMed 16352683 |
| Ipamorelin | No verifiable organism-level or human regimen identified | No published regimen reported here | Not established | The database category is an intended research area, not a demonstrated indication | No protocol met this article's primary-source standard; vendor schedules and related compounds were excluded. | No verified protocol located in the reviewed primary sources |
| IGF-1 LR3 | No verifiable organism-level or human regimen identified | No published regimen reported here | Not established | The database category is an intended research area, not a demonstrated indication | No protocol met this article's primary-source standard; vendor schedules and related compounds were excluded. | No verified protocol located in the reviewed primary sources |
| GHRP-2 | No verifiable organism-level or human regimen identified | No published regimen reported here | Not established | The database category is an intended research area, not a demonstrated indication | No protocol met this article's primary-source standard; vendor schedules and related compounds were excluded. | No verified protocol located in the reviewed primary sources |
| GHRP-6 | No verifiable organism-level or human regimen identified | No published regimen reported here | Not established | The database category is an intended research area, not a demonstrated indication | No protocol met this article's primary-source standard; vendor schedules and related compounds were excluded. | No verified protocol located in the reviewed primary sources |
| Sermorelin | No verifiable organism-level or human regimen identified | No published regimen reported here | Not established | The database category is an intended research area, not a demonstrated indication | No protocol met this article's primary-source standard; vendor schedules and related compounds were excluded. | No verified protocol located in the reviewed primary sources |
| MK-677 (Ibutamoren) | Healthy adults aged 64–81 years (n=32) | Oral placebo or 2, 10, or 25 mg once daily | Two separate study periods of 14 and 28 days | Growth-hormone and IGF-1 axis research | Ibutamoren is a non-peptide secretagogue; the short endocrine study did not establish a muscle, fat-loss, or longevity treatment. | Chapman et al., PubMed 8954023 |
| MK-2866 (Ostarine) | Healthy older men and postmenopausal women | Oral placebo, 1 mg, or 3 mg once daily | 12 weeks | Lean body mass and physical-function research | Enobosarm/Ostarine is a non-peptide investigational SARM; this phase 2 population and duration do not establish broader safety. | Dalton et al., PubMed 22031847 |
| RAD 140 (Testolone) | No verifiable organism-level or human regimen identified | No published regimen reported here | Not established | The database category is an intended research area, not a demonstrated indication | No protocol met this article's primary-source standard; vendor schedules and related compounds were excluded. | No verified protocol located in the reviewed primary sources |
| Hexarelin | Healthy adult men (n=12) | Single intravenous boluses of 0.5, 1, and 2 micrograms/kg in a rising-dose design | Single-dose endocrine challenge | Growth-hormone secretagogue pharmacology | Acute GH-response study, not a chronic body-composition protocol; route and population are not interchangeable with database schedules. | Imbimbo et al., PubMed 7957536 |
| Follistatin-344 | No verifiable organism-level or human regimen identified | No published regimen reported here | Not established | The database category is an intended research area, not a demonstrated indication | No protocol met this article's primary-source standard; vendor schedules and related compounds were excluded. | No verified protocol located in the reviewed primary sources |
Tissue repair, gut, and immune research
Repair and immune claims span animal injury models, barrier biology, and disease-specific human trials. A topical, oral, or injected study route is listed only when a source reported it.
| Database entry | Species or population | Route and historical study regimen | Duration | Indication or research question | Evidence limitation | Primary source |
|---|---|---|---|---|---|---|
| BPC-157 | Rats with transected Achilles tendons or medial collateral ligaments | Across the cited rat studies: intraperitoneal 10 micrograms/kg or 10 nanograms/kg once daily (the MCL study); the Achilles study also tested 10 picograms/kg, while the MCL study included local 1 microgram/g cream and drinking water at 0.16 microgram/mL | From 30 minutes after surgery until 24 hours before sacrifice; study-specific | Tendon and ligament healing | Preclinical injury models; no verified human therapeutic regimen and no animal-to-human conversion is appropriate. | Staresinic et al., PubMed 14554208 and Cerovecki et al., PubMed 20225319 |
| TB-500 | No verifiable organism-level or human regimen identified | No published regimen reported here | Not established | The database category is an intended research area, not a demonstrated indication | No protocol met this article's primary-source standard; vendor schedules and related compounds were excluded. | No verified protocol located in the reviewed primary sources |
| Thymosin Alpha-1 | No verifiable organism-level or human regimen identified | No published regimen reported here | Not established | The database category is an intended research area, not a demonstrated indication | No protocol met this article's primary-source standard; vendor schedules and related compounds were excluded. | No verified protocol located in the reviewed primary sources |
| KPV | No verifiable organism-level or human regimen identified | No published regimen reported here | Not established | The database category is an intended research area, not a demonstrated indication | No protocol met this article's primary-source standard; vendor schedules and related compounds were excluded. | No verified protocol located in the reviewed primary sources |
| Thymulin | No verifiable organism-level or human regimen identified | No published regimen reported here | Not established | The database category is an intended research area, not a demonstrated indication | No protocol met this article's primary-source standard; vendor schedules and related compounds were excluded. | No verified protocol located in the reviewed primary sources |
| Glutathione | No verifiable organism-level or human regimen identified | No published regimen reported here | Not established | The database category is an intended research area, not a demonstrated indication | No protocol met this article's primary-source standard; vendor schedules and related compounds were excluded. | No verified protocol located in the reviewed primary sources |
| LL-37 | No verifiable organism-level or human regimen identified | No published regimen reported here | Not established | The database category is an intended research area, not a demonstrated indication | No protocol met this article's primary-source standard; vendor schedules and related compounds were excluded. | No verified protocol located in the reviewed primary sources |
| Larazotide Acetate | Adults with celiac disease and persistent symptoms despite a gluten-free diet (n=342) | Oral 0.5, 1, or 2 mg three times daily, 15 minutes before meals | 12 weeks of treatment, preceded and followed by 4-week placebo phases | Celiac-symptom and intestinal-barrier research | The 0.5 mg group met the primary endpoint while higher doses did not; this is an investigational, disease-specific trial. | Leffler et al., PubMed 25683116 |
| GLP-2 (Glepaglutide) | Adults with short bowel syndrome and high stool output in a glepaglutide trial | Subcutaneous glepaglutide (a long-acting GLP-2 analogue), 0.1, 1, or 10 mg once daily | Three-week treatment periods in a randomized crossover design, separated by 4–8-week washouts | Intestinal adaptation and short-bowel-syndrome research | The cited study tested glepaglutide, not native GLP-2; its regimen must not be transferred to native GLP-2 or another analogue. | Naimi et al., PubMed 30880176 |
Cognition, sleep, and neuroprotection research
This category contains several mixtures and small molecules as well as peptides. A database label such as “nootropic” is not evidence of a validated human cognitive protocol.
| Database entry | Species or population | Route and historical study regimen | Duration | Indication or research question | Evidence limitation | Primary source |
|---|---|---|---|---|---|---|
| Pinealon | No verifiable organism-level or human regimen identified | No published regimen reported here | Not established | The database category is an intended research area, not a demonstrated indication | No protocol met this article's primary-source standard; vendor schedules and related compounds were excluded. | No verified protocol located in the reviewed primary sources |
| PE-22-28 | No verifiable organism-level or human regimen identified | No published regimen reported here | Not established | The database category is an intended research area, not a demonstrated indication | No protocol met this article's primary-source standard; vendor schedules and related compounds were excluded. | No verified protocol located in the reviewed primary sources |
| P-21 | No verifiable organism-level or human regimen identified | No published regimen reported here | Not established | The database category is an intended research area, not a demonstrated indication | No protocol met this article's primary-source standard; vendor schedules and related compounds were excluded. | No verified protocol located in the reviewed primary sources |
| Selank | No verifiable organism-level or human regimen identified | No published regimen reported here | Not established | The database category is an intended research area, not a demonstrated indication | No protocol met this article's primary-source standard; vendor schedules and related compounds were excluded. | No verified protocol located in the reviewed primary sources |
| Semax | No verifiable organism-level or human regimen identified | No published regimen reported here | Not established | The database category is an intended research area, not a demonstrated indication | No protocol met this article's primary-source standard; vendor schedules and related compounds were excluded. | No verified protocol located in the reviewed primary sources |
| Dihexa | No verifiable organism-level or human regimen identified | No published regimen reported here | Not established | The database category is an intended research area, not a demonstrated indication | No protocol met this article's primary-source standard; vendor schedules and related compounds were excluded. | No verified protocol located in the reviewed primary sources |
| 9-ME-BC | No verifiable organism-level or human regimen identified | No published regimen reported here | Not established | The database category is an intended research area, not a demonstrated indication | No protocol met this article's primary-source standard; vendor schedules and related compounds were excluded. | No verified protocol located in the reviewed primary sources |
| ARA 290 | Adults with type 2 diabetes and small-fiber neuropathy | Subcutaneous ARA-290 4 mg once daily | 28 days, with an additional 28-day observation period | Neuropathic symptoms and metabolic-control research | Small, indication-specific human trial; ARA-290 remains investigational and the observation period is not continued treatment. | Dahan et al., PubMed 25387363 |
| Cerebrolysin | No verifiable organism-level or human regimen identified | No published regimen reported here | Not established | The database category is an intended research area, not a demonstrated indication | No protocol met this article's primary-source standard; vendor schedules and related compounds were excluded. | No verified protocol located in the reviewed primary sources |
| CMS 121 | No verifiable organism-level or human regimen identified | No published regimen reported here | Not established | The database category is an intended research area, not a demonstrated indication | No protocol met this article's primary-source standard; vendor schedules and related compounds were excluded. | No verified protocol located in the reviewed primary sources |
| DSIP (Delta Sleep-Inducing Peptide) | No verifiable organism-level or human regimen identified | No published regimen reported here | Not established | The database category is an intended research area, not a demonstrated indication | No protocol met this article's primary-source standard; vendor schedules and related compounds were excluded. | No verified protocol located in the reviewed primary sources |
| VIP (Vasoactive Intestinal Peptide) | No verifiable organism-level or human regimen identified | No published regimen reported here | Not established | The database category is an intended research area, not a demonstrated indication | No protocol met this article's primary-source standard; vendor schedules and related compounds were excluded. | No verified protocol located in the reviewed primary sources |
| Cortexin | No verifiable organism-level or human regimen identified | No published regimen reported here | Not established | The database category is an intended research area, not a demonstrated indication | No protocol met this article's primary-source standard; vendor schedules and related compounds were excluded. | No verified protocol located in the reviewed primary sources |
Longevity and mitochondrial research
Longevity is an intended research theme, not a clinical indication. The strongest rows below are still either indication-specific human trials or tightly bounded animal experiments.
| Database entry | Species or population | Route and historical study regimen | Duration | Indication or research question | Evidence limitation | Primary source |
|---|---|---|---|---|---|---|
| Epitalon | No verifiable organism-level or human regimen identified | No published regimen reported here | Not established | The database category is an intended research area, not a demonstrated indication | No protocol met this article's primary-source standard; vendor schedules and related compounds were excluded. | No verified protocol located in the reviewed primary sources |
| NAD+ | No verifiable organism-level or human regimen identified | No published regimen reported here | Not established | The database category is an intended research area, not a demonstrated indication | No protocol met this article's primary-source standard; vendor schedules and related compounds were excluded. | No verified protocol located in the reviewed primary sources |
| SS-31 (Elamipretide) | Adults with genetically confirmed primary mitochondrial myopathy | Subcutaneous elamipretide 40 mg once daily in MMPOWER-3 | 24 weeks | Primary mitochondrial myopathy; six-minute-walk and fatigue outcomes | MMPOWER-3 did not improve six-minute-walk distance or fatigue versus placebo. As of 2026, elamipretide (Forzinity) has FDA accelerated approval only to improve muscle strength in adults and pediatric patients with Barth syndrome weighing at least 30 kg; that label and formulation do not establish a PMM or research-product protocol. | MMPOWER-3, PMC 10382259 and Forzinity FDA label |
| MOTS-C | Young CD-1 and C57BL/6J mice, plus middle-aged and old C57BL/6N mice | Intraperitoneal MOTS-c: 5 mg/kg/day for 2 weeks in young CD-1 mice; 5 or 15 mg/kg/day in a CD-1 high-fat-diet experiment; 15 mg/kg/day for 2 weeks in C57BL/6J and middle-aged/old C57BL/6N mice; a late-life arm used 15 mg/kg three times weekly | Study-specific: 2 weeks for the cited daily-dose experiments; one CD-1 high-fat-diet exercise readout followed 10 days of treatment, while the late-life arm was longitudinal intermittent dosing | Muscle homeostasis, insulin sensitivity, and exercise-capacity research | Mouse study; the amount is not a human dose and the peptide has no validated human protocol. | MOTS-c exercise and muscle study, PMC 7817689 |
| FOXO4-DRI | Naturally aged male mice | Intraperitoneal FOXO4-DRI 5 mg/kg every other day for three administrations | Markers were assessed 30 days after the dose series | Senescent-Leydig-cell and testosterone research | Aged-mouse senolytic study; no human pharmacokinetics, toxicology, or regulated human regimen exists. | Zhang et al., PubMed 31959736 |
| Humanin | No verifiable organism-level or human regimen identified | No published regimen reported here | Not established | The database category is an intended research area, not a demonstrated indication | No protocol met this article's primary-source standard; vendor schedules and related compounds were excluded. | No verified protocol located in the reviewed primary sources |
Skin and topical research
Cosmetic ingredients and matrix peptides are not interchangeable with injectable products. Where a regimen could not be verified in a primary publication, the entry is marked accordingly.
| Database entry | Species or population | Route and historical study regimen | Duration | Indication or research question | Evidence limitation | Primary source |
|---|---|---|---|---|---|---|
| GHK-Cu | No verifiable organism-level or human regimen identified | No published regimen reported here | Not established | The database category is an intended research area, not a demonstrated indication | No protocol met this article's primary-source standard; vendor schedules and related compounds were excluded. | No verified protocol located in the reviewed primary sources |
| SNAP-8 | No verifiable organism-level or human regimen identified | No published regimen reported here | Not established | The database category is an intended research area, not a demonstrated indication | No protocol met this article's primary-source standard; vendor schedules and related compounds were excluded. | No verified protocol located in the reviewed primary sources |
| PAL-AHK (Palmitoyl Tripeptide-1) | No verifiable organism-level or human regimen identified | No published regimen reported here | Not established | The database category is an intended research area, not a demonstrated indication | No protocol met this article's primary-source standard; vendor schedules and related compounds were excluded. | No verified protocol located in the reviewed primary sources |
Sexual, reproductive, and hormonal research
The human studies in this group are narrow—such as IVF trigger research or the approved bremelanotide indication—and should not be generalized to other hormonal goals.
| Database entry | Species or population | Route and historical study regimen | Duration | Indication or research question | Evidence limitation | Primary source |
|---|---|---|---|---|---|---|
| PT-141 | Premenopausal women with acquired, generalized HSDD | FDA label: subcutaneous bremelanotide 1.75 mg as needed at least 45 minutes before anticipated sexual activity; no more than one dose in 24 hours and eight doses per month | On-demand use in the approved indication; label does not define a continuous course | Acquired, generalized hypoactive sexual desire disorder | Bremelanotide is an FDA-approved drug for a defined population; the label is not evidence for PT-141 research products or other indications. | Current DailyMed label |
| Oxytocin | No verifiable organism-level or human regimen identified | No published regimen reported here | Not established | The database category is an intended research area, not a demonstrated indication | No protocol met this article's primary-source standard; vendor schedules and related compounds were excluded. | No verified protocol located in the reviewed primary sources |
| Melanotan 2 | No verifiable organism-level or human regimen identified | No published regimen reported here | Not established | The database category is an intended research area, not a demonstrated indication | No protocol met this article's primary-source standard; vendor schedules and related compounds were excluded. | No verified protocol located in the reviewed primary sources |
| Kisspeptin | Women undergoing IVF after ovarian stimulation | A single subcutaneous kisspeptin-54 injection at 1.6, 3.2, 6.4, or 12.8 nmol/kg | Single trigger; oocytes were retrieved 36 hours later | LH surge and oocyte-maturation research | A specialist IVF trigger study; it does not establish a general hormonal or libido protocol. | Kisspeptin-54 IVF study, PubMed 25036713 |
Other experimental entries
These entries are retained for database completeness. A name in the database is not evidence that a dose, route, duration, or human indication has been established.
| Database entry | Species or population | Route and historical study regimen | Duration | Indication or research question | Evidence limitation | Primary source |
|---|---|---|---|---|---|---|
| PNC-27 | No verifiable organism-level or human regimen identified | No published regimen reported here | Not established | The database category is an intended research area, not a demonstrated indication | No protocol met this article's primary-source standard; vendor schedules and related compounds were excluded. | No verified protocol located in the reviewed primary sources |
| MK-777 | No verifiable organism-level or human regimen identified | No published regimen reported here | Not established | The database category is an intended research area, not a demonstrated indication | No protocol met this article's primary-source standard; vendor schedules and related compounds were excluded. | No verified protocol located in the reviewed primary sources |
Why animal-to-human translation is not a dose conversion
An animal amount is not a human starting amount. Species differ in absorption, plasma protein binding, enzymatic cleavage, receptor distribution, immune recognition, renal and hepatic clearance, and disease biology. Even within one species, sex, age, strain, injury model, formulation, assay, and injection site can change exposure. A nominal amount per kilogram therefore cannot be converted operationally into a human schedule by arithmetic.
Responsible translation requires pharmacokinetics and pharmacodynamics (what exposure occurs and what biological response follows), formulation and bioavailability work, repeat-dose toxicology, immunogenicity assessment, reproductive and genotoxicity work where relevant, and validated analytical methods. A regulated clinical trial then establishes a monitored starting exposure, escalation rules, stopping criteria, adverse-event surveillance, and an indication-specific endpoint. Those safeguards are why the tables preserve study context instead of offering animal-to-human conversions.
Regulatory status is entry-specific
This database includes approved drugs and labeled indications alongside investigational compounds and non-peptide research chemicals. A compound may be approved for one indication while remaining investigational for another, as the elamipretide row illustrates. Check the cited label or current FDA source for the specific compound and indication.
What this index can—and cannot—establish
- It can document a historical regimen reported in a named study, including its population, route, duration, and research question.
- It cannot establish that a research-only product has pharmaceutical identity, sterility, potency, or freedom from endotoxin or immunogenicity risk.
- It cannot turn an approved label into permission to use a different formulation, route, population, or indication.
- It cannot validate a supplier's schedule, a social-media protocol, a stack, a cycle, or a dose copied from a related molecule.
- It cannot replace a protocol approved by an institutional review board or animal-care committee, a regulated trial, or qualified clinical and regulatory oversight.
Research-use boundary
For educational and laboratory-reference purposes only. Do not use this index as medical advice or as an operational administration guide. Research products may be mislabeled or contaminated, and human investigational use requires appropriate regulatory oversight.
Frequently Asked Questions
How many current database entries does this article cover?
It covers all 59 entries in the current Peptide Basics database. The tables are generated from the database array and each entry is classified into one intended-research group.
Does every entry have a verified dosing protocol?
No. 21 entries have a regimen supported here by a primary publication, registry, or FDA label. 38 entries are explicitly marked as having no verifiable protocol under the article's source standard.
Are the human amounts in this article recommendations?
No. Human amounts are historical facts from a named trial or label, presented with population, route, and duration. They are not prescriptions, and they do not establish a schedule for a different formulation, indication, or person.
Can an animal regimen be converted into a human regimen?
Not by a simple mg/kg calculation. Translation requires pharmacokinetic and pharmacodynamic modeling, formulation and bioavailability work, repeat-dose toxicology, immunogenicity assessment, and regulated clinical-trial oversight.
Are all entries research-only compounds without FDA approval?
No. The database includes approved drugs and non-peptide entries as well as investigational compounds. Approval and labeling are compound- and indication-specific; check the cited FDA label or current FDA source rather than applying a blanket status.
Why does the article sometimes say no verifiable protocol exists?
Because a database category or vendor schedule is not a verified study regimen. When the reviewed primary literature did not provide enough species or population, route, duration, indication, and amount detail, the article leaves the gap explicit instead of inventing a protocol.
Related Research Profiles
Semaglutide
Semaglutide is a long-acting glucagon-like peptide-1 (GLP-1) receptor agonist studied extensively in clinical research for its association with glycemic regulation, appetite signaling, and body-weight reduction.
Read profileTirzepatide
Tirzepatide is a dual glucose-dependent insulinotropic polypeptide (GIP) and glucagon-like peptide-1 (GLP-1) receptor agonist studied in clinical research for its association with glycemic regulation and body-weight reduction.
Read profileRetatrutide
Retatrutide is an investigational triple-receptor agonist studied in clinical research for its simultaneous activity at the GIP, GLP-1, and glucagon receptors and its association with large body-weight and metabolic changes.
Read profileBPC-157
BPC-157 is a synthetic pentadecapeptide derived from a sequence in gastric juice protein, studied in preclinical models for its association with angiogenesis, tissue-repair signaling, and cytoprotection.
Read profileCJC-1295
CJC-1295 is a synthetic growth-hormone-releasing hormone (GHRH) analogue studied in preclinical and clinical research for its association with stimulated growth-hormone and IGF-1 release.
Read profileMK-677 (Ibutamoren)
MK-677 (ibutamoren) is an orally active, non-peptide growth-hormone secretagogue and ghrelin-receptor agonist studied in clinical and preclinical research for its association with sustained, pulsatile growth-hormone and IGF-1 elevation.
Read profileSS-31 (Elamipretide)
SS-31 (elamipretide) is a mitochondria-targeting tetrapeptide studied for its selective association with the inner mitochondrial membrane lipid cardiolipin and its effects on mitochondrial bioenergetics in research models.
Read profileLarazotide Acetate
Larazotide acetate is a synthetic octapeptide studied in clinical and preclinical research as a tight-junction regulator that is associated with reduced intestinal permeability ('leaky gut').
Read profileReferences
- Wilding JPH, et al. Once-Weekly Semaglutide in Adults with Overweight or Obesity (STEP 1). N Engl J Med. 2021.Source
- Jastreboff AM, et al. Tirzepatide Once Weekly for the Treatment of Obesity (SURMOUNT-1). N Engl J Med. 2022.Source
- Jastreboff AM, et al. Triple-Hormone-Receptor Agonist Retatrutide for Obesity: A Phase 2 Trial. N Engl J Med. 2023.Source
- Lau DCW, et al. Once-weekly cagrilintide for weight management in people with overweight and obesity. Lancet. 2021.Source
- Falutz J, et al. Metabolic effects of a growth hormone-releasing factor in patients with HIV-associated lipodystrophy. N Engl J Med. 2007.Source
- U.S. FDA. EGRIFTA SV (tesamorelin) full prescribing information, 2024.Source
- U.S. FDA. FORZINITY (elamipretide) full prescribing information, 2025.Source
- U.S. FDA / DailyMed. VYLEESI (bremelanotide) prescribing information.Source
- Teichman SL, et al. Prolonged stimulation of growth hormone and IGF-I secretion by CJC-1295 in healthy adults. J Clin Endocrinol Metab. 2006.Source
- Imbimbo BP, et al. Growth hormone-releasing activity of hexarelin in humans: a dose-response study. Eur J Clin Pharmacol. 1994.Source
- Astrup A, et al. Effect of tesofensine on bodyweight loss, body composition, and quality of life in obese patients. Lancet. 2008.Source
- Chapman IM, et al. Stimulation of the growth hormone–IGF-I axis by daily oral MK-677 in healthy elderly subjects. J Clin Endocrinol Metab. 1996.Source
- Dalton JT, et al. The selective androgen receptor modulator GTx-024 (enobosarm) improves lean body mass and physical function. J Cachexia Sarcopenia Muscle. 2011.Source
- Karaa A, et al. Efficacy and safety of elamipretide in individuals with primary mitochondrial myopathy: the MMPOWER-3 randomized clinical trial. Neurology. 2023.Source
- Lee C, et al. MOTS-c is an exercise-induced mitochondrial-encoded regulator of age-dependent physical decline and muscle homeostasis. Nat Commun. 2021.Source
- Barnhart KF, et al. A peptidomimetic targeting white fat causes weight loss and improved insulin resistance in obese monkeys. Sci Transl Med. 2011.Source
- Dahan A, et al. ARA 290, a nonerythropoietic peptide engineered from erythropoietin, improves metabolic control and neuropathic symptoms in patients with type 2 diabetes. Mol Med. 2015.Source
- Leffler DA, et al. Larazotide acetate for persistent symptoms of celiac disease despite a gluten-free diet. Gastroenterology. 2015.Source
- Naimi RM, et al. Glepaglutide, a novel long-acting GLP-2 analogue, for patients with short bowel syndrome. Lancet Gastroenterol Hepatol. 2019.Source
- Jayasena CN, et al. Kisspeptin-54 triggers egg maturation in women undergoing in vitro fertilization. J Clin Invest. 2014.Source
- Zhang C, et al. FOXO4-DRI alleviates age-related testosterone secretion insufficiency by targeting senescent Leydig cells in aged mice. Aging (Albany NY). 2020.Source
- Staresinic M, et al. Gastric pentadecapeptide BPC 157 accelerates healing of transected rat Achilles tendon. J Orthop Res. 2003.Source
- Cerovecki T, et al. Pentadecapeptide BPC 157 improves ligament healing in the rat. J Orthop Res. 2010.Source
Research Use Only
For educational and laboratory-reference purposes only. This is a source-controlled index of historical study facts, not medical advice, a prescription, or an administration guide. The database includes approved drugs, non-peptide compounds, mixtures, and investigational entries; regulatory status is compound- and indication-specific. Research products are not necessarily approved, sterile, accurately labeled, or suitable for human use.